Vator Securities welcomes you to Vator Tech Days – Focus: Digital Health, a digital event where you get the opportunity to meet some of the most exciting and fast-growing companies within Digital Health.
The event is held completely digitally and takes place on April 20th at 12:55 to 17:00. The participating companies are Doktor.se, Dynamic Code, PainDrainer, AsthmaTuner, Visiba Care, Natural Cycles & Doctrin.
The event will focus on impactful growth companies within Digital Health and will end with a summary chat with the renowned investor Christian Hellman (Edastra).
On March 9th, Vator Securities held the first Vator Tech Days, focusing on SaaS companies. The event was an opportunity for investors to meet the most exciting and fast-growing companies within SaaS.
Participating companies were Lime Technologies, Irisity, Litium, ZignSec and 24SevenOffice.
The event was concluded with a summary chat with the renowned SaaS investor Johan Crona (Cloud Capital).
Watch the presentations from the attending companies.
Vator Securities advises Sprint Bioscience on 21 MSEK Directed Share Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 21 million.
Sprint Bioscience develops small-molecule first-in-class drug projects with a focus on oncology. With a fragment-based drug development method, the company develops drug projects in a time- and resource-efficient way that is outlicensed to global pharmaceutical companies during the preclinical phase.
read more
Vator Securities advises Epulze on 57 MSEK Private Placement
Vator Securities acts as Financial Adviser in connection with the transaction raising SEK 57 million.
Epulze gives amateur players of computer games like Dota 2 and Counter-Strike: Global Offensive, the opportunity to participate in tournaments, leagues, and matches where real money is at stake. Among the new investors are well-known names such as Svea Ekonomi and Norwegian Carucel Finance, while Knutsson Holdings increases its ownership in the company.
read more
Thou shall reimburse the one who finds the silent killer
It may seem trivial to point out by now, but an accurate distinction between surveillance and screening is important in order to properly understand IMMray PanCan-d’s intended use, clinical utility offer and the parameters of importance to access the viability of the test to be included in guidelines and gaining broad reimbursement.
We still see confusion here.
read more
Vator Securities advises CombiGene on 75 MSEK Rights Issue
Vator Securities acts as Financial Adviser in connection with the transaction raising approximately SEK 75 million.
Having established the production platform for CG01, CombiGene’s intention in 2021 is to focus on the final parts of the preclinical program for CG01 with two major preclinical studies, a biodistribution study and a safety study, which will be conducted together with CombiGene’s CRO partners Northern Biomedical Research and Neurochase.
read more
21 MSEK | Q2 2021
57 MSEK | Q2 2021
75 MSEK | Q1 2021
23 MSEK | Q4 2020
